文献速递淋巴瘤

BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的效力

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2021-01-01

本研究评估了BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病(CLL)患者中的体液免疫应答,并与年龄匹配的健康对照比较。共167例CLL患者接种两剂疫苗后抗体应答率为39.5%,显著低于对照组的100%。应答率受疾病活动性和治疗影响,現行治疗者应答率最低。

要点

  • CLL患者接种BNT162b2后抗体应答率仅39.5%,显著低于健康对照。
  • 接种时正在治疗者应答率16.0%,未治疗者55.2%,治疗后缓解者79.2%。
  • BTK抑制剂或维奈克拉±抗CD20治疗者应答率低(16.0%和13.6%)。

核心结论

  • CLL患者对BNT162b2 mRNA新冠疫苗的抗体介导应答明显受损,且受疾病活动性和治疗影响。

研究设计与样本

  • 研究纳入167例CLL患者,接种2剂BNT162b2疫苗(间隔21天),第二剂后检测抗体滴度。
  • 将52例CLL患者与52例性别年龄匹配的健康对照进行比较。

主要发现

  • 167例CLL患者总抗体应答率为39.5%。
  • 52例CLL患者与52例健康对照相比,应答率分别为52%和100%(调整OR 0.010,95%CI 0.001-0.162,P < .001)。
  • 治疗后临床缓解者应答率79.2%,未治疗者55.2%,接种时正在治疗者16.0%。
  • BTK抑制剂治疗者应答率16.0%,维奈克拉±抗CD20抗体治疗者13.6%。
  • 接种前12个月内暴露于抗CD20抗体者无一例应答。

关键数值与推荐

  • 多因素分析中应答的独立预测因素包括:较年轻年龄、女性、无当前活动性治疗、IgG ≥550 mg/dL、IgM ≥40 mg/dL。

临床怎么用

  • CLL患者接种BNT162b2后抗体应答率低,尤其正在接受BTK抑制剂、维奈克拉或近期抗CD20治疗者,需考虑额外防护策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 vaccine in patients with CLL. We evaluated humoral immune responses to the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine in patients with CLL and compared responses with those obtained in age-matched healthy control subjects. Patients received 2 vaccine doses, 21 days apart, and antibody titers were measured by using the Elecsys Anti-SARS-CoV-2 S assay after administration of the second dose. In a total of 167 patients with CLL, the antibody response rate was 39.5%. A comparison between 52 patients with CLL and 52 sex- and aged-matched healthy control subjects revealed a significantly reduced response rate among patients (52% vs 100%, respectively; adjusted odds ratio, 0.010; 95% confidence interval, 0.001-0.162; P < .001). The response rate was highest in patients who obtained clinical remission after treatment (79.2%), followed by 55.2% in treatment-naive patients and 16.0% in patients under treatment at the time of vaccination. In patients treated with either Bruton's tyrosine kinase inhibitors or venetoclax ± anti-CD20 antibody, response rates were considerably low (16.0% and 13.6%). None of the patients exposed to anti-CD20 antibodies <12 months before vaccination responded. In a multivariate analysis, the independent predictors of response were younger age, female sex, lack of currently active treatment, immunoglobulin G levels ≥550 mg/dL, and immunoglobulin M levels ≥40 mg/dL. In conclusion, antibody-mediated response to the BNT162b2 mRNA COVID-19 vaccine in patients with CLL is markedly impaired and affected by disease activity and treatment. This trial was registered at www.clinicaltrials.gov as #NCT04746092.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021. PMID: 33861303. doi:10.1182/blood.2021011568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。